Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
Portfolio Pulse from Lara Goldstein
Numinus Wellness' Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study on LSD compound MM-120 for General Anxiety Disorder. CCR has enrolled and dosed 19 trial participants and is enrolling volunteers at a second research clinic. Numinus is also a site for COMPASS Pathways' clinical trial of psilocybin therapy for Treatment-Resistant Depression.
June 05, 2023 | 8:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Numinus Wellness' Cedar Clinical Research is a site for COMPASS Pathways' ongoing clinical trial of psilocybin therapy for Treatment-Resistant Depression.
The partnership with Numinus Wellness' CCR will help COMPASS Pathways enroll participants for its clinical trial of psilocybin therapy for Treatment-Resistant Depression. This collaboration is crucial for the progress of the study and could potentially lead to positive outcomes, which may positively impact COMPASS Pathways' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
MindMed's Phase 2b study on LSD compound MM-120 for General Anxiety Disorder is enrolling participants at Numinus Wellness' Cedar Clinical Research.
The partnership with Numinus Wellness' CCR will help MindMed enroll participants for its Phase 2b study on LSD compound MM-120. This collaboration is crucial for the progress of the study and could potentially lead to positive outcomes, which may positively impact MindMed's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Numinus Wellness' Cedar Clinical Research is a top research site for MindMed's Phase 2b study and is also a site for COMPASS Pathways' clinical trial of psilocybin therapy.
Numinus Wellness' CCR is playing a significant role in the enrollment and progress of MindMed's Phase 2b study and COMPASS Pathways' clinical trial. This involvement in multiple high-profile studies showcases the company's research capabilities and may positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100